Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients

Trial Profile

Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs GALE 301 (Primary) ; GALE 302 (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 17 Mar 2017 According to a Galena Biopharma media release, data from this study was given during an oral presentation at the Annual Meeting on Women's Cancer 2017 hosted by the Society of Gynecologic Oncology.
    • 17 Mar 2017 Final analysis results published in a Galena Biopharma media release.
    • 09 Mar 2017 Status changed from active, no longer recruiting to completed, as reported in a Galena Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top